4,891 Shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Bought by Farringdon Capital Ltd.

Farringdon Capital Ltd. acquired a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 4,891 shares of the medical equipment provider's stock, valued at approximately $517,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of ZBH. Roman Butler Fullerton & Co. acquired a new position in shares of Zimmer Biomet during the fourth quarter worth $473,000. KLCM Advisors Inc. acquired a new position in shares of Zimmer Biomet in the fourth quarter valued at about $7,825,000. Peddock Capital Advisors LLC purchased a new position in Zimmer Biomet in the fourth quarter valued at $654,000. Van ECK Associates Corp boosted its stake in shares of Zimmer Biomet by 5.9% during the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock worth $417,814,000 after acquiring an additional 218,688 shares in the last quarter. Finally, Reinhart Partners LLC. increased its stake in shares of Zimmer Biomet by 34.4% in the 4th quarter. Reinhart Partners LLC. now owns 86,755 shares of the medical equipment provider's stock valued at $9,164,000 after purchasing an additional 22,220 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company's stock.

Zimmer Biomet Stock Performance

NYSE:ZBH traded up $1.85 during mid-day trading on Wednesday, reaching $99.29. The stock had a trading volume of 537,098 shares, compared to its average volume of 1,653,288. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The business has a 50 day simple moving average of $105.82 and a 200 day simple moving average of $106.62. The firm has a market capitalization of $19.64 billion, a price-to-earnings ratio of 22.31, a PEG ratio of 1.95 and a beta of 0.84. Zimmer Biomet Holdings, Inc. has a twelve month low of $93.10 and a twelve month high of $123.96.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the previous year, the firm posted $2.20 EPS. On average, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.97%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet's payout ratio is 21.57%.

Wall Street Analyst Weigh In

ZBH has been the subject of a number of research reports. Royal Bank of Canada cut their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. Truist Financial reissued a "hold" rating and issued a $113.00 target price (down from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. BTIG Research reiterated a "buy" rating on shares of Zimmer Biomet in a research report on Monday, April 14th. Stifel Nicolaus lifted their price target on Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a report on Thursday, January 23rd. Finally, JMP Securities reiterated a "market outperform" rating and issued a $140.00 price objective on shares of Zimmer Biomet in a report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, Zimmer Biomet currently has a consensus rating of "Hold" and a consensus target price of $124.15.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares in the company, valued at $915,379.20. The trade was a 14.13 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.70% of the company's stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.